Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα) positive breast cancer (BCa) patients are treated with adjuvant endocrine therapy2 including selective estrogen receptor modulators (SERMs) an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Genet
Autors principals: Magnani, Luca, Frige, Gianmaria, Gadaleta, Raffaella Maria, Corleone, Giacomo, Fabris, Sonia, Kempe, Mannus H., Vershure, Pernette J., Barozzi, Iros, Vircillo, Valentina, Hong, Sung-Pil, Perone, Ylenia, Saini, Massimo, Trumpp, Andreas, Viale, Giuseppe, Neri, Antonino, Ali, Simak, Colleoni, Marco Angelo, Pruneri, Giancarlo, Minucci, Saverio
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://ncbi.nlm.nih.gov/pubmed/28112739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3773
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars